Albany, Jan 24, 2019 (Issuewire.com) - Niemann-Pick Disease Type C (NP-C) - Market Insights, Epidemiology and Market Forecast-2028
The diagnosis rate of NP-C in the 7MM is assessed to be around 50% and is expected to increase in the coming years resulting in increased diagnosed population and ultimately higher treatable cases.
- The prevalence of NP-C is similar in both male and female
- According to DelveInsight, the total prevalent population of NP-C in the 7 major markets ranges from approximately 2115 cases in 2017.
- DelveInsight also estimates a higher prevalence of NP-C in the United States with approximately 1011 cases in 2017, followed by EU5 and Japan. Among the EU5 countries, Germany had the highest prevalent population of NP-C followed by the UK. Spain had the lowest prevalent population in 2017.
- The diagnosis rate of NP-C in the 7MM is assessed to be around 50% and is expected to increase in the coming years resulting in increased diagnosed population and ultimately higher treatable cases.
(Albany, US) DelveInsight launched a new report on Niemann-Pick Disease Type C (NP-C) - Market Insights, Epidemiology and Market Forecast-2028
Key topics covered
- The report gives a thorough understanding of the Niemann-Pick Disease Type C (NPC) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Niemann-Pick Disease Type C (NPC) in the US, Europe, and Japan.
- The Niemann-Pick Disease Type C (NPC) epidemiology division provide the insights about a historical and current patient pool and forecasted trend for every 7 major countries.
- The report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug.
- The report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The prevalence of NP-C in Western Europe (France, UK, and Germany) was estimated to be approximately 1/120,000 to 1/150,000 living births, based on diagnostic data.
Niemann-Pick Disease Type C (NP-C) is a progressive, irreversible, pan-ethnic and chronically debilitating neurovisceral Lysosomal Lipid Storage Disease, which is characterized by the visceral, neurological and psychiatric manifestations. It involves the unique abnormalities of intracellular transport of endocytosed cholesterol with sequestration of unesterified cholesterol in lysosomes and late endosomes. It ultimately results in the accumulation of cholesterol and glycosphingolipids in various neurovisceral tissues.
Based on the genes involved in the mutation, NP-C maybe classified as Niemann Pick Type C1 and Niemann- Pick Disease Type C2. Type C1 is caused by a mutation in NP-C1 gene and type C2 is caused by a mutation in the NP-C2 gene. Symptoms include sudden muscle problems such as seizures, clumsiness, tremors, problems walking, sudden falls, slurred speech and trouble in moving eyes up and down. In the majority of the cases, the neurological symptoms begin appearing in the ages of 4 to 10.
The therapeutic market of Niemann-Pick Disease Type C (NPC) in the seven major markets is expected to reach USD 162.30 million by 2028. The United States accounts for the largest market size of NPC, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The United States accounts for 32% of the total sales in 2017.
Companies covered
- Orphazyme
- Mallinckrodt
- CTD Holdings
- Intrabio
And many others
Drugs covered
- VTS-270
- Arimoclomol
- Trappsol Cyclo
And many others
1. Key Insights
2. Niemann-Pick Disease Type C (NPC) Market Overview at a Glance
2.1. Market Share (%) Distribution of Niemann-Pick Disease Type C (NPC) in 2016
2.2. Market Share (%) Distribution of Niemann-Pick Disease Type C (NPC) in 2027
3. Disease Background and Overview: Niemann-Pick Disease Type C (NPC)
3.1. Introduction
3.2. Classification of Niemann Pick Disease
3.3. Causes
3.4. Inheritance patterns
3.5. Clinical Manifestations
3.6. Pathophysiology
3.7. Diagnosis
3.7.1. NP-C Diagnostic Recommendations Expert Panel: Diagnostic Recommendations (2016)
3.7.2. NP-C suspicion index Tool
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Niemann Pick Disease Type-C
5. Country Wise-Epidemiology of NPC
5.1. United States
5.2. EU5 Countries
5.3. Germany
5.4. France
5.5. Italy
5.6. Spain
5.7. United Kingdom
5.8. Japan
6. Treatment Practices
7. Unmet Needs
8. Marketed drugs
8.1. Zavesca: Actelion Pharmaceuticals Ltd
9. Emerging drugs
9.1. Emerging Drugs Analysis
9.2. Arimoclomol: Orphazyme
9.3. VTS-270: Vtesse Inc. (Mallinckrodt)
9.4. Trappsol Cyclo (cyclodextrin): CTD Holdings, Inc.
10. Niemann Pick Disease Type C: 7 Major Market Analysis
11. Market Outlook by Country
12. The United States: Market Outlook
13. EU-5 Countries: Market Outlook
14. Japan: Market Outlook
15. Market Drivers
16. Market Barriers
17. Appendix
17.1. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprhensive solutions to improve their performance.
Contact us:
Shruti Thakur
+919650213330
Media Contact
Delveinsight Business Reserarch LLP
9193216187
304 S. Jones Blvd #2432, Las Vegas NV 89107
Source :Delveinsight Business Research LLP
PDF Version : issuewire.com/pdf/2019/01/niemann-pick-disease-type-c-np-c-market-insights-epidemiology-and-market-forecast-2028-IssueWire.pdf
This article was originally published by IssueWire. Read the original article here.
